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Abstract
The activation of IRF-3 during the early stages of viral infection is critical for the initiation of the antiviral response; however the activation of
IRF-3 in HIV-1 infected cells has not yet been characterized. We demonstrate that the early steps of HIV-1 infection do not lead to the activation
and nuclear translocation of IRF-3; instead, the relative levels of IRF-3 protein are decreased due to the ubiquitin-associated proteosome
degradation. Addressing the molecular mechanism of this effect we show that the degradation is independent of HIV-1 replication and that virion-
associated accessory proteins Vif and Vpr can independently degrade IRF-3. The null mutation of these two genes reduced the capacity of the
HIV-1 virus to down modulate IRF-3 levels. The degradation was associated with Vif- and Vpr-mediated ubiquitination of IRF-3 and was
independent of the activation of IRF-3. N-terminal lysine residues were shown to play a critical role in the Vif- and Vpr-mediated degradation of
IRF-3. These data implicate Vif and Vpr in the disruption of the initial antiviral response and point to the need of HIV-1 to circumvent the antiviral
response during the very early phase of replication.
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The innate immune response has developed as a rapid and
regulated defense mechanism in which the recognition of an
invading pathogenic organism induces multiple signaling path-
ways leading to the activation of transcription factors that controlAbbreviations: SeV, Sendai virus; NDV, Newcastle disease virus; ISG, Inter-
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coordination of the immune responses (Akira et al., 2006). An-
tiviral cytokines (interferons), activated as an early response to
infection, play an important role both in the outcome of the viral
infection and in its virulence (Samuel, 2001). Two families of
transcription factors play a major role in the transcriptional acti-
vation of Type I interferon genes (IFN A and B): the well-
characterized family of NFκB factors and a newly emerging
family of interferon regulatory factors (IRF) (Paun and Pitha,
2007) where IRF-3 and IRF-7 play a critical role in the Type I
IFN induction. In fact, genetically modified mice, in which
expression of these genes is suppressed, are highly susceptible to
viral infection (Sato et al., 2000). IRF-3 plays a key role in the
induction of IFNB and amplification of the antiviral response.
IRF-3 activity is controlled both by phosphorylation (Au et al.,
86 A. Okumura et al. / Virology 373 (2008) 85–971995; Juang et al., 1998; Fitzgerald et al., 2003; Sharma et al.,
2003) and proteasome-mediated degradation (Lin et al., 1998;
Saitoh et al., 2006).
A new dimension of complexity to the virus-mediated innate
immune response was recognized by the discovery that many
viruses have evolved mechanisms allowing them to overcome
the host-induced antiviral response either by direct interference
with the pathways leading to the transcriptional activation of
interferon genes, or with the IFN-induced antiviral state. Thus,
some of the viral genes, not directly required for viral replication,
such as the NS1 protein of influenza A (Smith et al., 2001), E3L
protein of poxviruses (Hornemann et al., 2003) or the Vp35
protein of Ebola virus (Hartman et al., 2006) are essential for
viral pathogenicity in vivo (Hengel et al., 2005).
The role of the innate antiviral response in HIV-1 infection
remains largely unexplored; however, the cellular cytidine deam-
inase APOBEC3G and several other members of the APOBEC3
family show a potent anti HIV-1 activity (Sheehy et al., 2002).
APOBEC3G is packaged into HIV-1 virions and blocks viral
replication by inducing cytidine to uracil deamination in the
newly transcribed single stranded proviral DNA. Most of the
uracil containing transcripts are degraded before integration
and viral replication (Mariani et al., 2003; Bishop et al., 2006).
However APOBEC3-mediated inhibition of HIV-1 was also
shown to be independent on the activity of cytidine deaminase
and editing (Chiu et al., 2005; Newman et al., 2005). The HIV-1
encoded accessory protein Vif counteracts function of APO-
BEC3G by targeting it for degradation by the ubiquitin pro-
teasome pathway (reviewed in Cullen, 2006; Ehrlich and Yu,
2006). Another accessory protein, Vpr, encapsulated in large
amounts in HIV-1 virions, induces degradation of cellular ura-
cil DNA glycosylase (UNG) and its variant SMUG, which
remove uracil both from single and double stranded DNA
(Schrofelbauer et al., 2005). Thus both Vif and Vpr may inhibit
APOBEC3G-induced antiviral effects.
While the expression of APOBEC3G is stimulated by Type I
interferon (Chen et al., 2006), analysis of the overall immune
response genes expressed during the early steps of HIV-1 in-
fection does not detect expression of IFNA or IFNB genes
(Vahey et al., 2002). The infection of human peripheral mono-
nuclear cells with T cell-tropic HIV-1 resulted in an overall
increase of genes associated with antiviral immune responses
(Vahey et al., 2002), and enhanced expression of chemokines
and cytokines was also detected in HIV-infected macrophages;
however, induction of Type I IFN or interferon-stimulated genes
(ISG) was not observed in either cell type in this study (Vazquez
et al., 2005). In contrast, Woelk et al. observed an up-regulation
of ISG in HIV-1-infected macrophages, but also did not detect
expression of Type I IFN genes (Woelk et al., 2004). Similarly,
expression of Type I IFN genes was not detected in HIV-1
infected immature dendritic cells (iDC) (Izmailova et al., 2003).
It is not clear how to reconcile the induction of the ISG in the
absence of stimulation of interferon synthesis, but it is likely
that some of these genes can be directly targeted by HIV-1-
stimulated signaling pathways.
Thus, viral control of IRF-3 activity limits not only expression
of IFN genes, but also of some ISG. However the activation ofIRF-3 by HIV-1 has not yet been defined. The objective of this
study was to analyze the activation of IRF-3 during the early steps
of HIV-1 infection. While HIV-1 infection did not lead to the
activation and nuclear translocation of IRF-3, the relative levels of
IRF-3 protein in cytoplasmwere decreased during the early stages
of HIV-1 infection by ubiquitin-associated proteosome-mediated
degradation. Addressing the molecular mechanism of this effect
we show that two HIV-1 accessory proteins, Vpr and Vif, target
IRF-3 for degradation. Null mutations in these two genes de-
creased the capacity of the virus to down modulate IRF-3. Thus,
Vpr and Vif disrupt an early antiviral response by mediating
proteasome degradation of IRF-3.
Results
IRF-3 is not activated during early stages of HIV-1 infection
Binding of HIV-1 virions to its receptors induces several
signaling pathways (Popik and Pitha, 1998, 2000). Binding of
HIV-1 envelope glycoprotein gp120 from R5 and R4 viruses to
chemokine receptors triggers tyrosine phosphorylation of Pyk2,
a focal adhesion component (Davis et al., 1997) and induces
calcium signaling (Weissman and Fauci, 1997). In addition
HIV-1-mediated signaling activates NFκB and AP-1, which re-
sults in aberrant expression of pro-inflammatory genes (Popik
and Pitha, 1998; Briant et al., 1998). The C-terminal phos-
phorylation of IRF-3 by two IκB kinases, TBK1 and IKKε, is
essential for the induction of Type I IFNs and some ISG
(Fitzgerald et al., 2003; Sharma et al., 2003). To investigate
whether binding of HIV-1 to its receptors is able to stimulate a
signaling pathway leading to the activation of IRF-3, Jurkat T
cells were incubated with HIV-1 for 1 h. Since Jurkat cells do
not induce significant levels of IFN upon infection with para-
myxoviruses such as Sendai virus (SeV) we used HeLa cells as
a positive control since SeV induces high levels of Type I IFN in
these cells. SeV infection induced various levels of IRF-3
phosphorylation compared to uninfected HeLa cells, here la-
beled IRF-3PI, PII, and PIII (Fig. 1A). It was previously shown
that PII and PIII represent C-terminal serine phosphorylation,
whereas PI results from phosphorylation at the N-terminus
(Servant et al., 2003), the latter being insufficient for the nuclear
translocation of IRF-3. HIV-1 infection of Jurkat cells, while
clearly inducing slowly migrating PI form of IRF-3, did not lead
to a complete phosphorylation of IRF-3. However, the degree to
which SeV and HIV-1 induce IRF-3 phosphorylation could
depend on incubation time with the virus. To discount this pos-
sibility an infection time course was analyzed (Fig. 1B). Fur-
thermore, in order to ensure that the difference in the IRF-3
phosphorylation pattern following SeVand HIV-1 infection was
not a consequence of analyzing two different immortalized cell
lines, peripheral blood mononuclear cells (PBMC) were in-
fected with either SeV or HIV-1. PBMC were used rather than
CD4+ HeLa cells, since in these cells HIV-1 infection was not
very effective and therefore would not allow to differentiate
between inhibition of IRF-3 phoispohorylation and lack of ac-
tivation due to low infection. Furthermore as HeLa cells are not
a natural host of HIV-1, results obtained in these cells could not
Fig. 1. IRF-3 is not activated and translocated to the nucleus during the early stages of HIV-1 infection. (A) Jurkat cells were incubated on ice with HIV-1 (NL4-3)
(moi 10) for 1 h prior to incubation at 37 °C for 1 h. HeLa cells were incubated with Sendai virus (SeV) (moi 5) for 2 h at 37 °C. Moi was calculated as described in
Materials and methods. Cells were then washed with PBS and harvested in NP40 lysis buffer. Soluble proteins were separated on 7.5% SDS PAGE, transferred to
PVDFmembrane, blotted with anti-IRF-3 polyclonal antibody and detected by ECL. (B) Time course of IRF-3 phosphorylation following virus infection. PBMCwere
incubated with HIV-1 (moi 5) or SeV (moi 5) in duplicate experiments to that described above. Samples were taken at the times indicated, lysates were prepared and
IRF-3 detected as described in A. Samples from control (0), SeVand TPA treated HeLa cells are shown for comparison of gel migration. (C) HIV-1 infection does not
induce nuclear translocation of IRF-3. PM1 cells were infected with HIV-1 (AD8) (moi 10) as described in Materials and methods. Cells were harvested at the indicated
times post infection and the levels of IRF-3 in the nuclear and cytoplasmic fractions were determined by immunoblotting. The equal amounts (15 μg) of protein were
loaded on the gel. Sp1 is a nuclear protein therefore its levels in nucleus were determined as a control for equal loading. Levels in cytoplasm were determined as a
control for the purity of nuclear fraction and absence of leaking of nuclear proteins to cytoplasm. The levels of β-actin were determined as controls for equal protein
loading.
87A. Okumura et al. / Virology 373 (2008) 85–97be generalized. In PBMC the majority of the constitutively ex-
pressed IRF-3 was present in the PI form; however IRF-3 PII
and PIII forms were readily detected within 1–2 h post SeV
infection (Fig. 1B). The PII and PIII forms of IRF-3 could be
also detected in HeLa cells at 4 h post SeV infection, however
the levels of IRF-3 were significantly lower than at 1 h post
infection (Fig. 1A) due to the virus induced degradation (Lin
et al., 1998). In contrast TPA treatment of HeLa cells did not
induce IRF-3 phosphorylation beyond the PI stage. HIV-1
infection of PBMC did not induce phosphorylation of IRF-3
beyond the PI form even at 4 h post infection. Phospho-serine
specific antibody recognizing phosphorylated serine in the
396–405 IRF-3 cluster (Servant et al., 2003) recognized IRF-3
in the SeV infected, but not in the HIV-1 infected cells. Fur-
thermore, HIV-1 infection did not induced formation of IRF-3
dimers that are specific for the C terminal phosphorylated IRF-3
(Yoneyama et al., 1998) (data not shown). These results indicate
that the binding of HIV-1 to its receptors and the early steps of
HIV-1 infection does not result in the C terminal phosphoryla-
tion of IRF-3. Accordingly, the early phase of HIV-1 infection
did not stimulate expression of Type I IFN genes in PBMC and
did not activate the synthesis of biologically active IFN (data
not shown).
Translocation of the IRF-3 to the nucleus is another indi-
cation of its activation and it is critical for the transcriptional
activation of IRF-3 stimulated genes (Lin et al., 1998; Yone-yama et al., 1998; Weaver et al., 1998). To determine whether
IRF-3 is activated at the later stages of HIV-1 infection, we have
analyzed the relative levels of nuclear and cytoplasmic IRF-3 in
HIV-1 infected monocytic PM1 cell line up to 48 h post HIV-1
infection. Fig. 1C shows that while low levels of nuclear IRF-3
could be detected in uninfected cells, no IRF-3 could be de-
tected in the nucleus of HIV-1 infected cells. As the control for
the purity of isolated nuclei and protein levels analyzed we
show that the levels of the nuclear transcription factor Sp-1
remain constant within 48 h post infection and that this factor is
detected only in the nucleus and not in the cytoplasm. The
majority of the IRF-3 both in infected and uninfected cells was
present in the cytoplasm (Fig. 1C), however its relative levels
were reduced within 2 h and did not reach baseline until after
12 h post infection. The constant levels of β-actin in the cy-
toplasmic extracts indicate that equal levels of protein were
analyzed. Altogether these data indicate that during the early
stages of HIV-1 infection, IRF-3 is not activated and does not
translocate to the nucleus.
HIV-1 infection induces degradation of IRF-3
Analysis of the relative expression levels of IRF-3 protein in
cells infected with HIV-1 (moi 10) has shown a decrease in the
first 2–24 h post infection (Figs. 1C and 2A). The quantitative
normalization of IRF-3 to β-actin shows that the decrease in the
Fig. 2. HIV-1 infection induces degradation of endogenous IRF-3. (A) PM1 cells were pre-treated with polybrene (5 ug/ml) for 1 h and infected with HIV-1, (AD8)
(moi 10) for 1 h at 4 °C. Cells were washed with PBS and incubate at 37 °C for indicated times. Cells were then collected and lysates were analyzed by Western blot
with IRF3, ISG15, HIV-1 and β-actin antibodies. Insert: The density of the IRF-3 bands was scanned, normalized to the density of the actin band and the values of the
controls were designated as 100%. The normalized integrated density values were plotted as a function of time. (B) Semi-quantitative RT-PCR of IRF3 transcripts in
HIV-1 infected PM1 cells. RNAwas isolated at indicated time post HIV-1 infection (moi 10), and amplified using IRF3 specific primers; the cDNAwere amplified in a
linear region of the PCR curve. The nucleotide sequences of the primers are given in Materials and methods. (C) Degradation of IRF-3 is inhibited by the proteasome
inhibitor (MG132). PM1 cells were treated with the proteasome inhibitor MG132 (5 uM) for 2 h, infected with HIV-1 (moi 10) and then incubated in the presence of
MG132 for indicated times. Cells were then collected, lysed and analyzed by Western blot for the presence of IRF-3, HIV-1 proteins and β-actin as described in
Materials and methods. (D) Azidothymidine (AZT) treatment does not prevent degradation of IRF3 in HIV-1 infected cells. PM1 cells were pre-treated with AZT
(10 μM) for 12 h and then infected with HIV-1. At indicated time post infection, cell lysates were immunoblotted with IRF3, HIV-1 and β-actin antibodies. Control
samples were pre-treated with AZT for 12 h and than treated with AZT for additional 12 h without HIV-1 infection. The 24 kDa band represent the in input virion p24.
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analyzed (Fig. 2 insert). The degree of inhibition was dependant
on the levels of the input virus infection, when cells were
infected with HIV-1 moi 1 the inhibition was insignificant (data
not shown). No decrease in IRF-3 levels was seen upon binding
of HIV-1 to the cells (within 1 h p.i. at 4 °C) and was used as a
control point.
The expression of the ubiquitin like protein ISG15 was
increased as early as at 6 h post infection and its conjugation
to cellular proteins was clearly seen at 24 h post infection
(Fig. 2A). Since ISG15 is induced both by IFN and activated
IRF-3, these data indicate that HIV-1 induced expression of ISG
is not mediated by activated IRF-3 or type I IFN (Haas et al.,
1987). The analysis of HIV-1-encoded proteins in infected cellshas shown decreasing levels of the virion p24 protein, while
newly synthesized Pr55 was detected only at 48 h post infec-
tion. These data indicate that the decrease in the IRF-3 levels
occurred prior to de novo synthesis of Gag protein (Fig. 2A).
The decrease in relative levels of IRF-3 could be due to the
inhibition of IRF-3 transcription or an increase in protein turnover.
There was no decrease in the relative levels of IRF-3 transcripts in
HIV-1 infected cells early after infection, as determined by semi-
quantitative PCR analysis (Fig. 2B). Instead, an increase of IRF-3
transcripts was observed at 24 h post infection coincidingwith the
expression of the early non-structural HIV-1 protein nef (data not
shown). We then tested whether the decrease in IRF-3 was due to
proteosomal degradation by determining the effect of the pro-
teosome inhibitor MG132 on the HIV-1-induced reduction of
Fig. 3. HIV-1 accessory proteins Vif and Vpr independently target IRF3 for
ubiquitin-mediated degradation. (A) 293T cells were co-transfected with IRF3
(0.5 μg) and indicated amounts of Vif plasmid (0–10 μg). The total amount of
transfected DNAwas held equivalent in all samples by using cDNA3.3 plasmid
DNA. 12 h after the transfection, cell lysates were analyzed byWestern blot with
IRF-3, Vif and β-actin polyclonal antibodies. The IRF-3 bands were scanned,
normalized to a density of the β-actin band and the values are expressed as % of
the normalized IRF-3 expressed in the absence of Vif that was nominated as
100%. (B) 293T cells were co-transfected with IRF3 and the Vpr plasmid of
indicated concentrations. The samples were analyzed for the presence of IRF-3
and Vpr and the relative levels of normalized IRF-3 were determined as des-
cribed above. Controls were transfected with the empty vector, pcDNA3.3 only.
Western blots show representative data of one from three independent ex-
periments. The error bars on the scan graph show variations between the in-
dividual experiments. Neither Vif nor Vpr induced IRF-3 degradation in the
presence of proteasome inhibitor MG132.
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infected cells treated with MG132 (at a concentration that did not
affect viability of the cells) (Fig. 2C), while the overall relative
level of IRF-3 was increased, indicating that constitutively ex-
pressed IRF-3 in the cells is regulated by proteosome degradation
and that HIV-1-mediated reduction of IRF-3 is also mediated
though proteosome degradation. The analysis of HIV-1 pro-
teins shows a significant inhibition of Pr55 synthesis (compare
Figs. 2A and C), which indicates that HIV-1 replication is in-
hibited in the presence of proteasome inhibitors (28).
To determine whether replication of the input viral genome is
required for IRF-3 degradation, PM1 cells were pretreated with
AZT before HIV-1 infection and the relative levels of IRF-3
were analyzed for 48 h post infection. AZT treatment effectively
inhibited HIV-1 replication and no synthesis of Pr55 could be
detected (Fig. 2D) while in the absence of AZT Pr55 was de-
tected as early as 48 h post infection (Fig. 2A). The AZT
treatment did not prevent IRF-3 degradation instead, blocking
of provirus formation and HIV-1 replication appeared to en-
hance reduction of IRF-3. The reason for enhancement of IRF-3
degradation in AZT treated cells is not clear, but it is not a
consequence of toxic effect of AZT, since the relative levels
of IRF-3 were not affected by AZT in uninfected controls
(Fig. 2D). These data indicate that the proteosomal degradation
of IRF3 is mediated by a component of HIV-1 virion, and does
not require virus replication.
Vif and Vpr independently target IRF-3 for ubiquitin-mediated
degradation
Two HIV-1 accessory proteins, Vif and Vpr, were previously
shown to induce degradation of distinct cellular proteins. Vif
targets APOBEC3G and 3F for proteasome degradation though
E3 ubiquitin ligase complex (SCF) containing Vif, Cul5, and
Elongin B/C (Yu et al., 2003; Wiegand et al., 2004; Marin et al.,
2003; Mehle et al., 2004a). To determine whether Vif can also
induce IRF-3 degradation, IRF-3 was expressed in the presence
of increasing levels of Vif (Fig. 3A). The steady-state levels
of IRF-3 were reduced by an increasing concentration of Vif;
however, even high levels of Vif were not able to completely
eliminate IRF-3 expression. Vif-mediated IRF-3 degradation
was inhibited in the presence of MG132. When the levels of
IRF-3 were normalized to the levels of β-actin, the inhibition
show a concentration dependence on the input Vif.
Vpr was shown to bind to UNG and SMUG and induce their
proteosome-mediated degradation by interacting with E3 ligase
components and forming complexes with Cul4 (Schrofelbauer
et al., 2005). Like Vif, expression of Vpr induced degradation of
ectopic IRF-3. The normalization of the IRF-3 levels to β-actin
levels has shown that Vpr induced degradation of IRF-3,
however the degradation was less effective than the degradation
by Vif (Fig. 3B). In the presence of proteosome inhibitor
MG132 neither Vif nor Vpr degraded IRF-3.
The Vif- and Vpr-mediated degradation was not limited to
ectopic IRF-3 as the levels of endogenous IRF-3 were also
decreased in cells expressing Vif or Vpr (Fig. 4A). The Vif- and
Vpr-mediated degradation of APOBEC3G or UNG respectively,was shown to be associated with the polyubiquitination of these
proteins. We have therefore examined whether Vif- and Vpr-
induced ubiquitination of IRF-3. 293T cells were co-transfected
with HA-tagged ubiquitin, IRF-3, and Vif or Vpr expression
Fig. 4. Vif and Vpr induce degradation of endogenous IRF-3 and its ubiquitination. (A) Vif and Vpr induce dose dependant degradation of the endogenous IRF3. 293T
cell were transfected with Vif or Vpr expressing plasmids and 12 h post transfection cells were harvested and cell lysates analyzed by immuno blotting with IRF-3, Vif
or Vpr and β-actin polyclonal antibodies (B). 293T cells were transfected with IRF-3 (1 μg) and Vif or Vpr (2 μg) and HA tagged, ubiquitin expressing plasmids-
UbHA (1 μg). The total amount of transfected DNAwas adjusted by pcDNA3.1 plasmid DNA. 24 h after the transfection, cell lysates were immunoprecipitated with
IRF-3 polyclonal antibodies and the precipitates were immuno blotted with monoclonal IRF-3 and HA antibodies. Controls were transfected with pcDNA3.3 only.
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noprecipitated with IRF-3 antibodies and the presence of IRF-3
and ubiquitinated IRF-3 was detected by immunoblotting
(Fig. 4B). While in the absence of Vif or Vpr, IRF-3 was de-
tected as single band with mobility of 55 kDa, in cell expressing
either Vif or Vpr an additional strong, slowly moving high mo-
lecular band and weak 65 kDa bands were detected (Fig. 4B). To
confirm that the high-molecular forms are ubiquitinated IRF-3,
the blots were reacted with anti HA antibodies. The ubiquitin
analysis detected high molecular form of IRF-3 but no 50 kDa
IRF-3 indicating that both Vif andVpr induce polyubiquitination
of IRF-3 (Fig. 4B).
Mapping of the IRF-3 lysine residues that are important for the
Vif- and Vpr-mediated degradation
Human IRF-3 contains 14 lysine residues, 11 of which are
located in the N-terminal half of the protein. To determine
whether the amino terminal peptide is susceptible to Vif- and
Vpr-mediated degradation, we co-transfected Vif or Vpr withIRF-3 or its deletion mutants encoding aa residues 1–269 or 1–
329, respectively. All IRF-3 plasmids were well expressed in
transfected cells and co-transfection with Vif or Vpr resulted in
reduction of relative levels of full size ectopic IRF-3 as well as
the two N terminal peptides (Fig. 5A). These data indicate that it
is the N terminal region of IRF-3, which contains signals re-
quired for the proteosomal degradation. It should be noted that
in these experiments the degradation of full-length IRF-3 was
insignificant while the N terminal peptides were degraded very
effectively. These data indicate that unphosphorylated full-
length IRF-3 is degraded less effectively than the short IRF-3
peptides. The β-actin levels were comparable in all samples
indicating equal loading.
To further identify the lysine residues that are critical for theVif-
and Vpr-mediated IRF-3 degradation we mutated 6 N terminal
lysines (residues 39, 77, 87, 105, 193) and one C terminal lysine
(K409) to arginine. All mutated IRF-3 plasmids were well ex-
pressed in transfected cells (Fig. 5B). When the mutated plasmids
and wt IRF-3 were co-transfected together with the Vif expressing
plasmid, all but the K87R and K105R mutants were degraded
Fig. 5. Mapping of IRF3 ubiquitination domain by Vif and Vpr. (A) 293Tcell were co-transfected with IRF-3 (1 μg) or its deletion plasmids encoding 1–269 and 1–329
aa long IRF-3 peptides andVpr or Vif expressing plasmids at the 1:1 IRF3:Vif or Vpr ratio. The total amount of transfected DNAwas kept constant. Cells were harvested
at 24 h post transfection and the relative levels of IRF-3, Vif andVpr (right-central panel) in cell lysates were determined by immune blotting with specific antibody. The
relative levels of actin were determined as controls for equal protein loading (B) IRF-3 (1 μg) and its respective K-R mutants were co-transfected together with Vif
plasmid (2 μg) to 293Tcells. Cell lysates were prepared 24 h later and relative levels of IRF-3 andVif determined byWestern blotting. (C) Transfection of IRF-3, its K-R
mutants and Vpr was done as described in B. The levels of β-actin were determined as controls for protein loading.
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expression ofVifwas comparable in all transfected samples. These
data indicate that the K87 and K105 play an important role in the
Vif-mediated proteasome degradation. Analysis of the β-actin
levels shows no major differences in protein loading between the
samples.
Co-transfection of the IRF-3 mutants with Vpr gave a slightly
different picture. Only the levels of wt IRF-3 and its K193R and
K409R mutants were effectively reduced by Vpr while mutation
of K39, K77R, K87, and K105 made IRF-3 resistant to Vpr-
mediated degradation. These data suggest that although both Vif
and Vpr target IRF-3 for proteosomal degradation, the IRF-3
lysines targeted by the Cul4 and Cul5 ubiquitin ligases may be
distinct. The analysis of the relative levels of β-actin in all
samples show that the observed differences are not consequence
of a difference in protein loading.HIV-1 mutants containing disrupted Vif and Vpr
To determine whether Vif and Vpr are essential for IRF-3
degradation in the context of viral infection we used mutants of
the pNL4-3HSA HIV-1 containing stop codon mutations in either
Vif or Vpr ORFs prematurely terminating Vif and Vpr translation
(Sakai et al., 2006). Jurkat cells were infected with wt HIV-1,
VSV-G pseudotype and the HIV-1 mutants and the HIV-1
proteins were detected by immune detection. It can be seen in
Fig. 6A that while both Vif and Vpr can be detected in cells
infectedwithwtHIV-1 orHIV-1VSV pseudotype, the insertion of
the stop codon into the respective accessory genes eliminates their
expression (Fig. 6A). The relative levels of IRF-3 were
determined in Jurkat cells infected with wt HIV-1 (pNL4-3HSA),
HIV-1-VSV pseudotype or the HIV-1-VSV mutants lacking
expression of Vif, Vpr, or both of these genes (Fig. 6B). Western
Fig. 6. Degradation of IRF3 is slow down in cell infected with HIV-1 mutant lacking both Vif and Vpr. (A) Analysis of the viral proteins expression encoded by
pNL4-3HSA modified by site-directed mutagenesis in Vif and Vpr genes. The pNL43 DNA or pNL4-3HSA DNA (2 μg) and its Vif and Vpr deletion mutants were co-
transfected together with the pMDG plasmid (1 μg) encoding VSV-G protein to 293T cells and 36 h post transfection, cell lysates were analyzed byWestern blotting
with HIV-1 antiserum and Vif or Vpr polyclonal antibodies. The Env− Vector cotransfected with pMDG served as a negative control. (B) Jurkat cells were infected
with Env− HIV-1 (NL43HSA) VSV pseudotype and VSV pseudotyped HIV-1 mutants (moi 10) lacking expression of either Vif, or Vpr or both of these genes. Cells
were harvested at indicated times post infection and the lysates were immunoblotted with polyclonal IRF3 antibody. Levels of β-actin were determined as controls
for protein loading. Western blot of a representative experiment is shown. The density of the IRF-3 bands was scanned, normalized to the density of the actin band
and the normalized integrated density values were plotted as a function of time. The data represent analysis of three independent infections.
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either Vif or Vpr gene alone is not sufficient to inhibit IRF-3
degradation. The silencing of bothVif and Vpr genes in the HIV-1genome slowed down IRF-3 degradation in the initial stages of
infection. There was no degradation in cells infected with the
double deleted mutants of HIV-1 at 2 h and small level of
Fig. 7. Vif andVpr inhibit IRF3-mediated activation of IFNB promoter. (A) 293T
cells were co-transfected with IRF-3 (1 μg) and IFNB promoter-luciferase re-
porter plasmids (0.5 μg) in the presence or absence of Vif or Vpr expressing
plasmids (1 μg). Cells were infected with NDV (moi 5) 12 h after the transfection
and harvested for luciferase activity 16 h post infection. Renila construct was
used as control for transfection efficiency. Luciferase activity was analyzed as
described in Materials and methods. (B) 293T cells transfected with indicated
amounts of NL4-3 proviral DNA (1 μg), were transfected with IRF-3 expressing
plasmid (1 ug) and IFNB luciferase reporter plasmid (0.5 μg). When indicated,
cells were also infected with NDV (moi 5) 12 h after IRF-3 transfection and
harvested and analyzed as described in A.
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IRF-3 levels were similar to those detected in cells infected
with wt HIV-1 or the single mutants. To determine whether the
observed difference between the effect of the double deleted
mutant HIV-1 and the wt or single deletedmutants was significant
and reproducible, the relative intensity of IRF-3 from three
independent infections was normalized to the intensity of β-actin
and expressed as function of time. The analysis has shown that the
IRF-3 degradation was slow down during the initial stages of
infection with the Vif and Vpr deleted mutant, when compare to
the infection with wt HIV-1 or single deleted mutants. These data
indicate that while over expressed ectopic Vif or Vpr alone are
sufficient to induce proteasome degradation of IRF-3, in the
context of viral particle the levels of Vif and Vpr are much lowerand only mutation in of both Vif and Vpr can stabilize IRF-3, but
the stabilization effect diminishes with the progression of viral
infection. We have also tested whether the Vif and Vpr deleted
HIV-1 mutants can activate IRF-3 and its nuclear translocation.
However our results indicate that the infection of PM1 cells with
the Vif and Vpr deletion mutants neither induces IRF-3 di-
merization or nuclear translocation. These data suggest that the
lack of IRF-3 activation in HIV-1 infected cells is not due to the
Vif and Vpr induced degradation of IRF-3.
Impairment of IRF-3-mediated activation
Our results indicate that Vif and Vpr induce proteasome-
mediated degradation of constitutively expressed IRF-3. In cells
infected with paramyxoviruses or treated with dsRNA, activated
IRF-3 is part of a multi-component transcriptional complex-
enhanceosome containing IRF-3, IRF-7, NFκB, and AP-1 as-
sembled on the promoter of the IFNB gene (Wathelet et al., 1998).
To determine whether Vif and Vpr inhibit the IRF-3-mediated
activation of the IFNB promoter, we have analyzed the IRF-3-
mediated stimulation of the IFNB promoter in NDV infected cells
expressing Vif or Vpr. 293T cells were co-transfected with IRF-3
and a reporter plasmid expressing the luciferase gene under the
control of IFNB promoter in the presence or absence of Vif or Vpr
expressing plasmids. Transfected cells were infected with NDV
and the relative levels of IRF-3 and the luciferase activity was
measured 16 h after the infection. As shown previously, NDV-
mediated activation of the IFNB promoter was increased by
ectopic IRF-3 (Schafer et al., 1998; Juang et al., 1998) but this
increase was nearly abolished in the presence of Vif or Vpr
(Fig. 7A). These results indicate that Vif and Vpr disrupted the
transcriptional activity of IRF-3. However, it is unlikely that the
Vif- or Vpr-mediated inhibition of the IFNB promoter is entirely
due to the degradation of IRF-3 since both the ectopic and
endogenous IRF-3 could still be detected in cells transfected with
Vif or Vpr (Fig. 7A). We therefore examined whether in HIV-1
infected cells the NDV-mediated activation of IRF-3 pathway is
impaired. NDV, like SeV, activates IRF-3 by the RIG I pathway
(Yoneyama et al., 2004), which leads to activation of IRF-3 and
IRF-7 and increases expression of the IFNB gene. Since HIV-1
does not infect CD4 negative cells, IRF-3 activation was analyzed
in 293T cells transfected with HIV-1 (NL4-3) proviral DNA.
Transfection of HIV-1 provirus into these cells leads to a single
cycle infection, expression ofHIV-1 proteins and release of virions
(Okumura et al., 2006). The results in Fig. 7B show that NDV-
mediated activation of IRF-3 signaling pathway was impaired in
cells transfected with HIV-1. Interestingly, while HIV-1 alone did
not stimulate the IFNBpromoter in these cells, the luciferase levels
were higher in NDV-infected cells expressing NL4-3 than in NDV
infected cells. Thus the previously demonstrated activation of
NFκB and AP-1 by HIV-1 infection may contribute to the NDV-
mediated activation of the IRF-3 pathway.
Discussion
The activation of IRF-3 during the early steps of viral
replication is a critical step in the initiation of the cellular
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steps of HIV-1 infection do not lead to the activation of IRF-3
and its nuclear translocation, but instead target the endogenous
cytoplasmic IRF-3 for ubiquitin-associated proteosome degra-
dation. The virion-associated HIV-1 accessory proteins Vpr and
Vif play a central role in IRF-3 degradation and the elimination
of Vpr andVif genes in anHIV-1 provirus decreased the capacity
of the virus to down modulate IRF-3 levels at the early stages of
viral infection. We have shown in this study that Vpr and Vif
disrupt the initial antiviral response by mediating the protea-
some-dependent degradation of IRF-3. Two specific lysine re-
sidues (K87 and K105) in the N-terminal region of IRF-3 play a
critical role in Vif-mediated degradation, while Vpr-mediated
degradationwas dependant onK39,K77,K87, andK105. Further
analysis will be needed to determine whether this N-terminal
region of IRF-3 represents the IRF-3 degron that targets activated
IRF-3 for ubiquitin-mediated degradation (Varshavsky, 1997). It
was shown recently that Pin1 induces a selective degradation of
the activated, but not the constitutive IRF-3 (Saitoh et al., 2006).
In contrast, Vif- and Vpr-mediated degradation of IRF-3 was not
dependent on its activation by C-terminal phosphorylation.
This study shows that Vif-mediated protein degradation is
not limited to APOBEC3G but affects another antiviral factor,
IRF-3. The degradation of APOBEC3G is mediated by direct
binding of Vif to APOBEC3G, which though its zinc-binding
motif also binds to the Cullin (Cul)-dependent ubiquitin ligase
SCF complex containing Cul5, Elongins B/C and the Ring
protein Rbx (Yu et al., 2003; Mehle et al., 2004b). Vpr binds
UNG and induces ubiquitination and proteasome degradation of
UNG by forming a complex with Cul4 (Schrofelbauer et al.,
2005). However, while Vif and Vpr induced ubiquitination of
IRF-3, direct binding of Vif or Vpr to IRF-3 was not detected
(data not shown). Both Vpr and Vif are incorporated into HIV-1
virions. Vpr is effectively packaged into the virions via inter-
action with p6 domain of Gag. According to a recent estimate
the ration of Vpr and capsid protein is 1:7 and HIV-1 particle
contains about 275 molecules of Vpr and 1800 molecules of
capsid (Muller et al., 2000). Vif is packaged into virions with
genomic RNA as a nucleoprotein complex. While Vif is effi-
ciently packaged into virions from acutely infected cells (60–
100 copies per virion), packaging from chronically infected
cells is very low (4–6 copies per virion) (Kao et al., 2003). Thus
while the levels of viron-associated Vpr are relatively high, the
levels of virion-associated Vif depend on type of infection and
can be substantially lower.
A number of viruses redirect the cellular ubiquitination
machinery to target the antiviral defense mechanisms. The spe-
cificity of ubiquitin conjugation to cellular proteins is deter-
mined by E3 ubiquitin ligase that selects the substrate as well as
the multi-protein complexes that contain the cullin Ring ubi-
quitin ligase. The cullin Ring ligases are activated by nedylation
(conjugation of Nedd8) and by the Ring protein Roc1 that
interacts with the ubiquitin ligase E2 (reviewed in Barry and
Fruh, 2006). Recruitment of the substrate to cullin ligase occurs
though specific linkers and adaptors that interact with cullin.
Cullin 5 interacts with elongin B and C that recognize the SOCS
box in the substrate adaptors. This mechanism is used by Vif toeliminate APOBEC3G (Yu et al., 2003). Vpr was shown to
associate with cullin 4 (Schrofelbauer et al., 2005), which
interacts with DDB 1 (DNA damage binding protein 1). The
simian virus 5 encoded V protein, which like Vif contains a
zinc-binding domain, interacts with cullin 4–DDB1 complex
and targets STAT-1 for degradation. On the other hand, para-
myxovirus V protein targets STAT2 and mumps V protein in-
duces degradation of both STAT1 and STAT3 (reviewed in
Horvath, 2004). The fact that both Vif and Vpr target IRF-3 for
degradation, presumably by association with cullin 5 and cullin
4 respectively, indicate that the functions of the cullin contain-
ing complexes may be multifunctional. Additional experiments
are in progress to identify the linker and the adaptor that interact
with IRF-3 in cullin containing complexes.
Constitutive over-expression of ectopic IRF-3 in T cells and
monocytes prior to infection inhibits de novo HIV-1 replication
indicating that the disruption of IRF-3 pathway enhances HIV-1
replication (unpublished data). However, the decrease in IRF-3
was observed only during the first 24 h post infection, sug-
gesting that during the later course of infection cells, HIV-1
counteract the Vif- and Vpr-mediated degradation of IRF-3. The
increase in the relative levels of IRF-3 transcripts coincides with
the synthesis of HIV-1 proteins, suggesting that IRF-3
transcription may be stimulated by an HIV-1 gene product.
We have also shown recently that the ubiquitin-like protein
ISG15 inhibits proteosome-mediated degradation of cellular
proteins including IRF-3 and intervenes with their ubiquitina-
tion (Lu et al., 2006). Whether ISG15, which is induced in HIV-
1 infected cells and conjugated to cellular proteins, attenuates
the Vif- and Vpr-mediated degradation is under investigation.
In conclusion these results indicate that HIV-1, like other
RNAviruses developed specific mechanism to down regulate the
early antiviral response (Basler and Garcia-Sastre, 2002). IRF-3
constitutes a component of the innate immune system that
induces expression number of cellular genes, including Type I
IFN genes and Rantes (Lin et al., 1999). Vpr and Vif are con-
served in primary virus isolates and are incorporated in virions.
The finding that virion proteins Vif and Vpr induce degradation
of IRF-3 in a co-operativemanner points out to the need ofHIV-1
to circumvent the antiviral response during the very early phase
of viral replication. Our results also suggest that the antiviral
compounds targeting the Vif- and Vpr-induced ubiquitination
will not only block viral replication, but also restore the basal
levels of IRF-3 and rescue the activity of the IRF-3-mediated
pathway.
Materials and methods
Cell culture, plasmids and virus
293T cells were cultured in DMEMwith 10% FBS. PM1 cell
line, which is CD4+CXCR4+CCR+ derivative of Hut79T cells
(Lusso et al., 1995), was cultured in RPMI medium 1640 with
10% FBS and 5 mM L-glutamine. The peripheral blood leuco-
cytes (PBMC) were prepared from buffy coats by FicolPaque
Plus gradient separation (AmershamPharmacia Biosciences) and
cultured at 1×106 cells/ml in RPMI 1640 with 10% FCS, 2 mM
95A. Okumura et al. / Virology 373 (2008) 85–97glutamine (Invitrogen Life Technologies). They were treated
with 25 mM 5 phorbol 12-tetradecanoate 13-acetate (TPA) for
24 h before HIV-1 infection.
The Vif and Vpr expression plasmid were described (Mehle
et al., 2004a; Schrofelbauer et al., 2005). The hemagglutinin
(HA)-tagged Ub plasmid (Ub-HA) was obtained from Dr. H.
Gottlinger (Harvard Medical School, Boston) and pCMV IRF3
was described (Au et al., 1995). pNL4-3HSA Vif-, pNL4-3HSA
Vpr- and pNL4-3HSA Vif–Vpr-plasmids were kindly obtained
from Dr. M. Leonardo (National Institute of Health, Bethesda)
(Sakai et al., 2006). The macrophage-tropic HIV-1 AD8 was
obtained from Dr Martin (National Institutes of Health,
Bethesda).
Infectious virus was produced and purified as described pre-
viously (Okumura et al., 2006). The pLN43 virus was titrated on
Jurkat cells and AD8was titrated on PM-1 cells. Moi of infection
was calculated as number of cpm (determined by RT assay)/cell
or by number of TCID50/cell. For the HIV-1 infection, cells
were incubated with HIV-1 (moi 10, unless specified otherwise))
for 1 h at 4 °C, than extensively washed and incubated for an
indicated time at 37 °C.
NL4-3HSA Vif-, pNL4-3HSA Vpr- and pNL4-3HSA Vif–Vpr-VSV
pseudotype virus
NL4-3HSA Vif-, pNL4-3HSA Vpr- and pNL4-3HSA Vif–Vpr-
pseudotyped virus stocks were produced in 293Tcells and pseudo
typed by using vesicular virus (VSV) G protein to replace Env
(Burns et al., 1993). To this effect HIV-1 plasmids were co-
transfectedwith pMDGplasmid encodingVSVGprotein, to 293T
cells and the virus containing supernatants were harvested 48 h
after transfection. Cellular debris was removed by centrifugation
and virus was purified as described before (Okumura et al., 2006).
Virus titers were determined by RTassay (Vicenzi and Poli, 1994)
and moi calculated as described above.
Transfection, immunoprecipitation, and Western blot analysis
For transfection, 293T cells were transfected with IRF-3
expressing plasmid (0.5–1.0 μg) and indicated amounts of Vif
or Vpr plasmids (1–10 μg) and when indicated ubiquitin
expressing plasmid (2 μg) using Lipofectamine Plus (In vitro-
gene). Total amount of plasmid DNA transfected was kept
constant in all samples by using empty pcDNA3 vector. At
indicated time post transfection cells were collected and cell
lysate analyzed by Western blot or immunoprecipitated using
specific antisera. The protein concentration in cell lysates was
determined by the Biorad protein assay.
The IRF3 and hemagglutinin (HA) antibodies were purchased
from Santa Cruz Biotechnology. Human serum, which detects
HIV-1 proteins, was a generous gift from Dr. M. Martin. The
Western blot analysis and immunoprecipitations of cell lysates
were described recently (Okumura et al., 2006). Briefly, cells were
lysed in lysis buffer (20 mM Tris–HCl/150 mM NaCl/10 mM
EDTA/0.5% Nonidet P-40/PMSF, and proteinase inhibitor
mixture). For the immunoprecipitation, 1 mg of protein was
incubated for 30 min on ice with 20 μl of protein G-agarose(Invitrogen) in a total volume of 1ml. Themixturewas centrifuged
at 1000×g for 5 min to preclear the lysate of proteins binding
nonspecifically to the matrix. The precleared supernatants were
incubatedwith specific antibody (2mg/ml) for 1 h on ice, and then
20 μl of protein G plus-agarose was added to the immune
complexes for an additional 1 h on ice. The bound proteins were
pelleted at 1000×g for 5 min and washed with lysis buffer thee
times. The final pellets were re-suspended in 40 μl of sample
buffer and boiled for 5 min before loading on a 10–13% SDS/
PAGEgel. The co-precipitated proteinswere identified byWestern
blotting. For Western blot analysis, cells were lysed in buffer
(20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate and protease
inhibitor mixture) and the lysates were clarified by centrifugation
at 10,000×g for 10 min. Proteins (10–50 μg) were separated on
10% or 13% SDS-polyacrylamide gels and electrotransferred to
the membranes (Bio-Rad). The membranes were blocked in 5%
nonfat milk for 30min at room temperature and then subsequently
incubatedwith primary antibody for 30min in blocking buffer and
with the horseradish peroxidase-conjugated secondary antibody
(1:10,000 dilutions; Amersham Pharmacia). Immunodetection
was realized by ECL reagents (Amersham Biosciences) and
autoradiography on hyperfilm MP (Amersham Biosciences).
Luciferase assay and RT PCR analysis
For the luciferase assay 293Tcells were transfected with IRF-3
expressing plasmid (1 μg) using Lipofectamine 2000 (Invitrogen)
and the IFNB promoter reporter–luciferase reporter plasmid
(0.5 μg) and Vpr or Vif expressing plasmid (1 μg). Alternatively
cells were transfected with IRF-3 (0.2 μg), IFNB-luciferase
reporter (0.5 μg) and pNL43 proviral DNA at 1:1 IRF3:pLN43
ratio. Renila plasmid was used as control for transfection effi-
ciency. The final concentration of transfected DNA was kept
constant in all co-transfection assays. Transfected cells were
infected with NDV 12 h post transfection and cells were lysed,
16 h later. Luciferase activity was measured as described pre-
viously (Lu et al., 2000), all samples were normalized to the
constant level of Renila luciferase.
Semi-quantitative RT-PCR analysis was described pre-
viously (Au et al., 2001).The IRF-3 specific primers used
were: 5′ primer CTGAAGCGGCTGTTGGTG and 3′ primer
ACCATGAGGAGCGAGGGC.
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